Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2023 Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2023 Earnings Call Transcript May 10, 2023

Matinas BioPharma Holdings, Inc. reports earnings inline with expectations. Reported EPS is $-0.03 EPS, expectations were $-0.03.

Operator: Greetings and welcome to the Matinas BioPharma First Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jody Cain. Thank you, Jody. You may begin.

Jody Cain: This is Jody Cain with LHA. Thank you for participating in today’s call. Speaking on today’s call from Matinas BioPharma will be Jerry Jabbour, Chief Executive Officer; Dr. Terry Matkovits, Chief Development Officer, Dr. Terry Ferguson, Chief Medical Officer; and Keith Kucinski, Chief Financial Officer I would like to remind listeners that remarks made during this call may state management’s future intentions, hopes, beliefs, expectations or projections. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements are made pursuant to the Safe Harbor provisions of the federal securities laws. These forward-looking statements are based on Matinas BioPharma’s current expectations and actual results could differ materially.

As a result, you should not place undue reliance on forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Matinas BioPharma files with the Securities and Exchange Commission. These documents are available in the Investors section of the company’s website and on the SEC’s website. Furthermore, the content of this conference call contains information that is accurate only as of the date of the live broadcast, May 10, 2023. Matinas BioPharma undertakes no obligation to revise or update any statements to reflect events or circumstances, except as required by law. And now I’d like to turn the call over to Jerry Jabbour.

Jerry?

Operator: Jerry is your line on mute?

Jerry Jabbour: Thank you, Jody. Good afternoon, everyone and thank you for joining us. We have several recent developments to discuss today. First, we are encouraged by the feedback from the FDA that provides us with valuable guidance in developing a Phase 3 trial design with MAT2203, our oral amphotericin B product, which we believe could position this important and potentially life-saving drug for the broadest label possible for the treatment of numerous invasive fungal infections. It’s not often that the Director of the Division of Infectious Diseases elects to join a Type B meeting. And we believe this is a signal of the broad support we are receiving within FDA for the development of MAT2203. We also announced earlier today that our initial in vivo study of oral messenger RNA delivery did not demonstrate preclinical activity, which resulted in the conclusion of our collaboration agreement with BioNTech.

Following a few brief remarks on these developments, I will turn the call over to Dr. Terry Matkovits to provide a more detailed update on MAT2203 and our plans to pursue marketing approval, followed by Dr. Terry Ferguson to discuss this recent development with BioNTech and our other nucleic acid programs. Finally, Keith Kucinski will review our financial results for the first quarter. You may have seen findings from a recent government study that was widely covered in the media discussing the rapid spread of deadly fungal infections in U.S. healthcare facilities. This disturbing news provides us with an even greater motivation to advance our MAT2203 program through late-stage development for broad treatment of these often deadly invasive fungal infections and toward commercialization.

Our optimism for the life-saving potential for our drug has increased as we have continued to amass impressive compassionate use data through our expanded access program. One particularly compelling case was even highlighted during the recent European congress of Clinical Microbiology and Infectious Diseases or ECCMID, which was held last month. This growing body of clinical evidence played a meaningful role in our recent FDA meeting held in April. During our March investor call, we announced that preparations were underway for a Type B meeting seeking the FDA’s guidance and agreement on the design of a Phase 3 clinical trial to assess the efficacy, safety, and tolerability of MAT2203 in patients with life-threatening invasive fungal infections or ifs.

Strategically, we believe that the treatment of these IFIs with our broad spectrum and orally administered antifungal agent, MAT2203, represents an important unmet medical need. It also aligns with the commercial interests of potential partners and sources of non-dilutive government funding to support the complete development and hopefully ultimate approval of MAT2203. We are diligently working to finalize and submit a protocol and accompanying statistical package for FDA review in the next few weeks. Once we have agreement with FDA on the design and endpoint to this Phase 3 study in aspergillosis, and other IFIs, hopefully in June, we’ll finalize our plan submission to BARDA and make a new submission to the Advanced Research Projects Agency for Health or ARPA-H.

This is a research funding agency within the NIH, which has a $2.5 billion annual budget directed at supporting transformative biomedical and healthcare breakthroughs. On the partnership front, we remain in dialogue with multiple potential, global and regional partners and are prepared to accelerate those discussions with this important FDA feedback in hand. Turning now to BioNTech, we were disappointed to learn that our initial in vivo study of oral mRNA delivery, which was based upon encouraging early in vitro results did not demonstrate preclinical activity. We recognize that this was an ambitious goal for a first in vivo study of a new, unique messenger RNA formulation, especially where, to date, no delivery technology has been successful in achieving oral delivery of messenger RNA.

We are pleased to report that in other studies conducted by Matinas similar messenger RNA formulations have shown activity when administered both intramuscularly and intraperitoneal. And we are encouraged by their ability to maintain both structural stability and undiminished biological activity for prolonged periods. We continue to believe that our technology has potential to provide differentiated delivery of nucleic acids, and this potential has been recognized by numerous parties outside of our relationship with BioNTech. To that end, we are in the process of generating additional data in this area, both through our collaboration with National Resilience, which has expanded to include studies with messenger RNA following April expiration of exclusivity with BioNTech and our own internal Matinas discovery programs in the siRNA space.

Dr. Ferguson will have more on this shortly. With those comments, I would now like to turn the call over to Dr. Terry Matkovits. Terry?

Terry Matkovits: Thanks, Jerry. And good afternoon everyone. As Jerry mentioned, we recently received official minutes from a very productive meeting with the FDA held in April. We believe that the written feedback reflects the clinical benefit the agency sees in developing a safe, targeted, orally administered form of amphotericin B for the treatment of patients with life-threatening IFIs. FDA also expressed its desire to continue to work collaboratively with us to advance development of MAT2203, while also acknowledging the impressive novelty of our LNC platform technology and its unique pharmacokinetic profile for the delivery of amphotericin B without the toxicity associated with IV administration. Importantly, the FDA provided us with the valuable guidance for pursuing MAT2203 registration in a broader IFI indication.

The agency was encouraged by the impressive results from our EnACT Phase 2 trial in cryptococcal meningitis, which demonstrated that our LNC platform was able to deliver amphotericin B in a safe, well-tolerated oral form across the blood-brain barrier with unprecedented survival outcome for oral antifungal therapy. During our meeting, FDA advised us that a larger Phase 3 trial focused solely on cryptococcal meningitis would be challenging to establish the pharmacodynamic bridge necessary to support a pharmacodynamic bridge necessary to support a streamlined 505(b)(2) approval pathway in broader IFI indications since MAT2203 would be administered as combination treatment with flucytosine or fluconazole. While surprising, following robust discussion with FDA, we now believe that the revised Phase 3 aspergillus IFI study design, assessing the efficacy and safety of MAT2203 as early step down monotherapy in a comparative non-inferiority Phase 3 trial in aspergillus should establish the desired pharmacodynamic bridge to unlock the 505(b)(2) pathway to indications for the treatment of other invasive fungal infections.

We expect this strategy to result in the broadest possible label for MAT2203, utilizing the most efficient clinical development pathway. Now let’s take a look at our Phase 3 strategy. We are designing this trial to include a comparative study targeting a single IFI, the deadly fungal infection aspergillosis and will include both first- and second-line treatment indications. The main aspergillosis cohort in this new trial design will include a non-inferiority comparison with standard of care IV azole or IV amphotericin B with a step down to oral azole or oral MAT2203 as monotherapy treatment beginning as early as two days after treatment with IV amphotericin B. The proposed trial will also include an additional cohort in a non-randomized experimental arm of patients with a broad range of probable or proven IFIs who are not able to step down to oral azole therapy.

The IFIs in this cohort will likely include invasive mucormycosis and other rare mold infections, invasive candidiasis, candida cystitis and endemic mycoses, including coccidioidomycoses, histoplasmosis and blastomycosis. Our strategy of including a cohort with a broader group of IFIs will benefit from leveraging the pharmacodynamic bridge we expect to establish in the comparative aspergillosis portion of the Phase 3 trial. We plan to capitalize upon this bridge to justify label expansion to IFIs under the 505(b)(2) pathway and to continue to qualify for QIDP incentives under the FDA priority review and Fast Track designation, as well as orphan drug exclusivities that could allow for 12 years of exclusivity protection in the U.S. and possibly 10 years in the EU.

We are in the process of finalizing this revised Phase 3 protocol for submission to FDA later this month, and FDA has agreed to review the protocol and provide comments on an off-cycle basis. This benefits us from a timing perspective and is another example of the FDA working collaboratively with us. We also expect this collaborative spirit to impact agreement on the acceptable non-inferiority margin for the main aspergillus cohort in this trial, which will directly impact the size of this cohort and the overall timing for study completion. During our meeting, FDA also recognized the clinically meaningful outcomes from compassionate use patients receiving MAT2203 as part of our expanded access program. While the case numbers are limited, the data demonstrates the ability of MAT2203 to safely target and effectively eradicate several invasive fungal infections even in the most clinically challenging cases.

Since beginning this program in August of last year we have received inbound requests from physicians at the National Institutes of Health, University of Michigan, Nationwide Children’s Hospital and Johns Hopkins among others on behalf of patients who have experienced significant renal toxicity while receiving IV amphotericin B and/or have not responded to or are unable to tolerate azole or other classes of antifungal. To date, seven patients with various life-threatening fungal diseases including: candida, aspergillosis, mucormycosis, coccidioidomycosis, fusarium, rhodotorula and protothecal infections have been treated with MAT2203 as part of our program. These infections have presented across various tissues in the body, including bone, skin, lung, sinus, bladder and the brain or central nervous system.

Treatment courses with MAT2203 administered as monotherapy have ranged from two weeks to six months or longer with no evidence of any renal toxicity. Off the seven patients five have successfully completed treatment with resolution of the infection with one patient, discontinuing treatment for reasons unrelated to MAT2203. Renal function for the patients return to normal after switching to MAT2203 with no further need for any electrolytes supplementation. Additionally, all were discharged from the hospital soon after switching to MAT2203 and received treatment on an outpatient basis. Of note, the pace of inbound request for our expanded access program has increased following a highly impactful case study presented at ECCMID last month as Jerry mentioned.

We will continue to identify and support requests for access where the compassionate use of MAT2203 makes sense for the patient and presents opportunities to generate additional meaningful clinical data outside of the clinical trial setting. I’d now like to turn the call over to Dr. Terry Ferguson to discuss our nucleic acid programs. Terry?

Terry Ferguson: Thanks Terry, and good afternoon everyone. We very recently received results of an initial in vivo study of an oral mRNA delivery formulation that was conducted in collaboration with BioNTech. The results did not demonstrate oral preclinical activity. By way of background this study was conducted in healthy mice and involved oral administration of a unique, proprietary, non-LNC formulation of BioNTech-supplied reporter firefly luciferase mRNA. This new proprietary, phosphatidylserine-containing nano-formulation is distinct from our conventional LNCs, and was developed by scientists at Matinas to handle the physical complexity and biological fragility of mRNA and other large oligonucleotides. We had been quite optimistic about moving into the oral study as this new delivery technology had successfully delivered mRNA in vitro in multiple cell lines.

Because of the timelines required under the BioNTech collaboration we opted to bring it forward for oral in vivo evaluation. Unfortunately, we were not successful in this initial study and our collaboration agreement with BioNTech has been concluded. In parallel to our work with BioNTech, we conducted additional internal in vivo studies with similar non-LNC mRNA formulations, and these have shown significant activity with systemic administered both intramuscularly and intraperitoneally. Our new mRNA formulations have also demonstrated impressive structural stability and continued biological activity out to at least 17 weeks at 4-degree Celsius, which compares favorably to lipid nanoparticles or LNPs. Matinas has filed numerous provisional patent applications based on these novel, unique phosphatidylserine-based formulations.

With the exclusivity constraints of the BioNTech agreement expiring last month, we were able to pursue interest from others working with mRNA. We have taken this opportunity to shift our work under our agreement with national resilience to focus more on mRNA, including in vitro delivery of reporter oligonucleotides with LNP reference comparators, delivery of even larger reporter oligonucleotides, and ultimately extending this work to include delivery of therapeutic oligonucleotides such as Cas9 mRNA, both in vitro and in vivo. Current plans involve a move into initial in vivo studies in the third quarter of this year. We envision that national resilience could be a true platform partner for our technologies by bringing to the table their considerable CMC expertise, their substantial manufacturing scale, and their unparalleled industry relationships in the nucleic acid space.

We’re also continuing our internal discovery work with smaller oligos such as short interfering RNA or siRNA with specific inflammatory and oncology targets. We have chosen to focus these internal efforts on smaller oligos because of the greater ease, which with – with which they can be encapsulated into traditional LNCs. The previously documented success of traditional LNC of small oligos in prior in vitro and in vivo studies, and the overall success of the LNC platform in the oral delivery of small molecules. Following initial in vitro testing with cargoes that include new therapeutic agents we intend to move forward with multiple in vivo bio-distribution and animal efficacy studies in the second half of 2023. Data from these studies are expected to be highly useful in positioning Matinas for developing a broader potential pipeline of ASO and siRNA therapeutics.

Now, I’d like to turn the call over to Keith Kucinski to review our first quarter financial performance. Keith?

Keith Kucinski: Thank you, Terry. Today we reported revenue for the first quarter of 2023 of $1.1 million, which was generated from our research collaborations with BioNTech and Genentech. We had no revenue for the first quarter of 2022. Total cost and expenses for the first quarter of 2023 were $6 million compared with $7 million for the first quarter of 2022, the decrease was primarily attributable to lower manufacturing costs of clinical trial materials partially offset by higher headcount. Our net loss for the first quarter of 2023 was $5.5 million or $0.03 per share, this compares with the net loss for the first quarter of 2022 of $6 million, also $0.03 per share. Our cash, cash equivalents and marketable securities as of March 31, 2023 were $24.9 million. Based on current projections, we believe our cash is sufficient to fund planned operations into the second half of 2024. With that, I’ll turn the call back to Jerry.

Jerry Jabbour: Thanks Keith. In summary, MAT2203 has been established as a highly promising treatment for serious and often deadly fungal infections. Survival data from our Phase 2 EnACT study in cryptococcal meningitis combined with the growing evidence of clinical impact in the treatment of invasive fungal infections through compassionate use in our expanded access program have provided a solid basis upon which to engage FDA in a thoughtful and productive discussion on the Phase 3 program designed to have the broadest clinical impact, resulting in a significant commercial opportunity for potential partners. FDA’s feedback, guidance and willingness to engage collaboratively have placed us in a stronger position to advance development of this life-saving drug.

We’re excited to finalize and submit our planned protocol to FDA for final review and obtain a big piece of the puzzle on unlocking partner value and government funding support. We remain on track with a later stage impactful clinical asset and one we continue to build a company around. While the recent in vivo study result with a novel oral messenger RNA delivery formulation, we conducted with BioNTech may represent a short-term setback. We are reminded that our goal of oral delivery of messenger RNA is ambitious and has to date not been accomplished by anyone else. Through our collaboration with BioNTech, we generated promising in vitro data followed by in vivo data demonstrating that our delivery technology could successfully deliver large nucleic acids like messenger RNA systemically.

Even if the Holy Grail of oral delivery remains elusive at this point in time. We remain committed to expanding our understanding of the capabilities of our platform technologies and continue to believe they have the potential to provide differentiated delivery of nucleic acids through programs with National Resilience with messenger RNA and internal programs focused on LNC delivery of siRNA and small molecules. The second half of this year should yield multiple opportunities for additional data and expansion of our platform. We’re grateful for your continued support and will continue to diligently advance our promising technologies and resulting therapies for the benefits of patients globally. With that, we have finished our prepared remarks.

And I will now turn the call back over to our operator, Paul, to facilitate a question-and-answer session. Paul?

Operator: Thank you. [Operator Instructions]

Jerry Jabbour: Thanks Paul. While we’re waiting for that first question, I’d like to mention that we have been invited to present at the JMP Healthcare Conference next Monday, May 15 in New York. The presentation will be webcast and will be available on the IR calendar page of the company website. Okay, Paul, can we have that first question, we’re ready.

Q&A Session

Operator: Thank you. Our first question is from Gregg Alexander [ph] with Truist. Please proceed with your question.

Operator: Thank you. Our next question is from Julian Harrison with BTIG. Please proceed with your question.

Operator: There are no further questions at this time. I’d like to hand the floor back over to Jerry Jabbour for any closing comments.

Jerry Jabbour: Thanks, Paul. Thanks to everyone for joining us today and for your interest in Matinas. We are very excited about our company’s future, we are very excited about our ability to save lives with MAT2203 and we are very excited about the potential we have with a number of different delivery technologies going forward in nucleic acid. We look forward to reporting our progress during our Q2 investor call in August. And should we have developments before then, we certainly will be informing the market as soon as we can. Thanks, and have a great evening.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.